Sodium glucose cotransporter 2 inhibitors: New horizon of the heart failure pharmacotherapy

Table 3 Summary of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure and the EMPEROR-Reduced trials

Ref.	Population (n)	Patients with T2DM	Intervention	Follow-up period (median)	Main results
DAPA-HF[22]	HFrEF with or without T2DM (4744)	42%	Empagliflozin	18 months	CV death or HF (HR, 0.71; 95%CI, 0.65–0.85)
					HF (HR, 0.70; 95%CI, 0.59–0.83)
					CV death (HR, 0.82; 95%CI, 0.69–0.98)
EMPEROR-Reduced[9]	HFrEF (3730)	49.8%	Empagliflozin	16 months	CV death or HF (HR, 0.75; 95%CI, 0.65–0.86)
					HF (HR, 0.69; 95%CI, 0.59–0.81)
					CV death (HR, 0.92; 95%CI, 0.75–1.12)

T2DM: Type 2 diabetes mellitus; CV: Cardiovascular disease; HF: Heart failure; HR: Hazard ratio; CI: Confidence interval.

.